Mesenchymal Stem/Stromal Cell Therapy for Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit
- 15 Downloads
Purpose of Review
Clinical trials of mesenchymal stem/stromal cell (MSC) therapy for bronchopulmonary dysplasia (BPD) are already underway. A thorough understanding of the preclinical work that underpins these trials is critical for neonatal practitioners to properly evaluate them.
The more significant advances have been in investigating the mechanisms of action by which MSCs are thought to ameliorate BPD, and the recognition that this therapeutic effect is largely contained within the non-cellular exosome fraction of MSCs.
In rodent hyperoxia models of BPD, MSCs have a pro-angiogenic effect mediated largely by vascular endothelial growth factor (VEGF) and shift the balance of endogenous lung cells from a pro-inflammatory to a pro-healing phenotype. MSC-derived exosomes can recapitulate these effects.
KeywordsMesenchymal stem cells Mesenchymal stromal cells Bronchopulmonary dysplasia Rodent hyperoxia models Neonatal intensive care unit
The author would like to thank Jessica Shui for her contributions to earlier versions of this work, and Thomas Hooven for critical review of the manuscript.
Compliance with Ethical Standards
Conflict of Interest
The author declares that there is no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393–403.Google Scholar
- 5.Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–74.Google Scholar
- 19.•• Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180:1122–30. Reference 19 is one of the original studies to identify a beneficial effect of MSCs on experimental BPD. CrossRefGoogle Scholar
- 20.•• van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180:1131–42. Reference 20 is one of the original studies to identify a beneficial effect of MSCs on experimental BPD. CrossRefGoogle Scholar
- 25.Sung DK, Chang YS, Ahn SY, Sung SI, Yoo HS, Choi SJ, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology. Almeida-Porada GD, editor. PLoS One. 2015;10:e0135574.CrossRefGoogle Scholar
- 26.• Chang YS, Choi SJ, Ahn SY, Sung DK, Sung SI, Yoo HS, et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. Covas DT, editor. PLoS One. 2013;8:e52419. Careful analysis of timing of MSC administration with relation to possible mechanism. CrossRefGoogle Scholar
- 29.Luan Y, Zhang L, Chao S, Liu X, Li K, Wang Y, et al. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGFb-1 signaling. Oncotarget. 2016;7:47082–94.Google Scholar
- 33.Chou H-C, Li Y-T, Chen C-M. Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Am J Transl Res. 2016;8:342–53.Google Scholar
- 34.Chen C-M, Lin W, Huang L-T, Chou H-C. Human mesenchymal stem cells ameliorate experimental pulmonary hypertension induced by maternal inflammation and neonatal hyperoxia in rats. Oncotarget. 2017;8:82366–75.Google Scholar
- 36.• Reiter J, Drummond S, Sammour I, Huang J, Florea V, Dornas P, et al. Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. Respir Res. 2017;18:137. Good mechanistic study examining effects of SDF-1 in MSC therapy. CrossRefGoogle Scholar
- 38.•• Al-Rubaie A, Wise AF, Sozo F, De Matteo R, Samuel CS, Harding R, et al. The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice. Respir Res. 2018;19:114. Interesting investigation of lung alveolar phenotype in experimental BPD and impact of MSCs. CrossRefGoogle Scholar
- 41.•• Chang YS, Ahn SY, Jeon HB, Sung DK, Kim ES, Sung SI, et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury. Am J Respir Cell Mol Biol. 2014;51:391–9. Good mechanistic study examining the effects of manipulating VEGF levels. CrossRefGoogle Scholar
- 42.Jiménez J, Lesage F, Richter J, Nagatomo T, Salaets T, Zia S, et al. Upregulation of vascular endothelial growth factor in amniotic fluid stem cells enhances their potential to attenuate lung injury in a preterm rabbit model of bronchopulmonary dysplasia. Neonatology. 2018;113:275–85.CrossRefGoogle Scholar
- 44.•• Chaubey S, Thueson S, Ponnalagu D, Alam MA, Gheorghe CP, Aghai Z, et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. Stem Cell Res Ther. 2018;9:173. Thorough evaluation of role of TSG-6 in MSC exosomes and their impact on experimental BPD. CrossRefGoogle Scholar
- 45.Porzionato A, Zaramella P, Dedja A, Guidolin D, Van Wemmel K, Macchi V, et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Cell Mol Physiol. 2019;316:L6–19.CrossRefGoogle Scholar
- 46.• Ahn SY, Park WS, Kim YE, Sung DK, Sung SI, Ahn JY, et al. Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury. Exp Mol Med. 2018;50:26. Good study demonstrating that VEGF in MSC exosomes has significant beneficial effect on experimental BPD. CrossRefGoogle Scholar
- 47.•• Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197:104–16. Excellent study linking MSC exosomes and modulation of lung macrophage phenotypes. CrossRefGoogle Scholar